Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Mylan Seeks To Buy Rival Perrigo
by Michael McCoy
April 13, 2015
| A version of this story appeared in
Volume 93, Issue 15
The generic drug maker Mylan has proposed to acquire its rival Perrigo in a cash and stock deal valued at close to $29 billion. The combined firm would be one of the world’s leading suppliers of generic and over-the-counter drugs, with annual sales of more than $15 billion. Mylan and Perrigo are both former U.S.-based firms that incorporated in Europe through inversion acquisitions: Mylan bought Abbott’s European generics business last year, and Perrigo acquired Ireland’s Elan in 2013. Perrigo says it has received the proposal and that its board will discuss it.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X